

***GF/B44/EDPO4 Decision on the Secretariat's Recommendation on Funding from the 2020-2022 Allocation***

Approved on 10 December 2020

***The Board:***

- 1. Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B43/ERO3 ("Table 1");***
- 2. Acknowledges each country disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;***
- 3. Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and***
- 4. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.***

***This decision does not have material budgetary implications for operating expenses.***

**Table 1: Secretariat's Recommendation on Funding from the 2020-2022 Allocation**

N	Applicant	Disease Component	Grant Name <sup>1</sup>	Grant End Date	Currency	Total Program Budget <sup>2</sup>	Catalytic Funds in Grant	Domestic Commitment <sup>3</sup>	Unfunded Quality Demand
1	<a href="#">Burundi</a>	HIV/TB	BDI-C-UNDP	31-12-23	US\$	44,840,462	-	HIV: 5,183,481; TB: 1,273,375	19,898,168
2	<a href="#">Congo</a>	Malaria	COG-M-CRS	31-12-23	EUR	29,070,712	-	4,689,897	2,650,379
3	<a href="#">Guatemala</a>	HIV/AIDS	GTM-H-INCAP	31-12-23	US\$	26,581,388 <sup>4</sup>	-	100,920,140	-
4	<a href="#">Haiti</a>	HIV/TB	HTI-C-WV	31-12-23	US\$	79,144,246	-	HIV: 6,954,510; TB: 4,852,016	21,825,141
5	<a href="#">Indonesia</a>	TB	IDN-T-PBSTPI	31-12-23	US\$	26,461,010	2,988,420	498,167,347	81,535,827
6	<a href="#">Madagascar</a>	TB	MDG-T-CRS	31-12-23	US\$	15,094,285	-	HIV: 24,675; TB: 3,880; Malaria: 5,061,844; RSSH: 12,140,464	6,403,165
7	<a href="#">Mauritius</a>	HIV/AIDS	MUS-H-NAS	31-12-23	US\$	2,265,213	-	679,564	801,200
8	Mozambique	<a href="#">HIV/AIDS</a>	MOZ-H-FDC	31-12-23	US\$	83,256,029	9,000,000	Indicative amounts: HIV: 97,476,480; TB: 16,785,140; Malaria: 13,233,564; RSSH: 90,159,335	162,013,433
9			MOZ-H-MOH	31-12-23	US\$	382,706,224	5,400,000		
10		<a href="#">HIV/TB</a>	MOZ-C-CCS	31-12-23	US\$	59,170,102	2,000,000		
11		<a href="#">TB</a>	MOZ-T-MOH	31-12-23	US\$	48,779,616	6,000,000		

<sup>1</sup> The Grant names are subject to change based on the ISO code.

<sup>2</sup> The Program budget for the Grant may be higher than the Program budget being recommended to the Board for approval where Covid-19 Response Mechanism funding has been integrated into the Grant.

<sup>3</sup> Domestic commitments pertain to the disease programs and exclude other specific commitments for RSSH, unless otherwise specified. Commitments for disease specific programs and RSSH are subject to local currency value fluctuation against US dollar and Euro currencies. Please note that the domestic commitments included in this report are recorded as of GAC date and may be updated during implementation for countries that have been granted policy flexibilities.

<sup>4</sup> The Program budget includes US\$971,794 of private sector contribution.

N	Applicant	Disease Component	Grant Name <sup>5</sup>	Grant End Date	Currency	Total Program Budget <sup>6</sup>	Catalytic Funds in Grant	Domestic Commitment <sup>7</sup>	Unfunded Quality Demand
12	Myanmar	<a href="#">HIV/AIDS</a>	MMR-H-SCF	31-12-23	US\$	39,572,600	1,936,991	48,000,000	74,136,985
13			MMR-H-UNOPS	31-12-23	US\$	89,135,961	4,363,009		
14		<a href="#">TB</a>	MMR-T-SCF	31-12-23	US\$	16,781,101	1,015,741	55,402,125	
15			MMR-T-UNOPS	31-12-23	US\$	82,345,154	4,984,259		
16	<a href="#">Pakistan</a>	Malaria	PAK-M-DOMC	31-12-23	US\$	20,767,377	-	86,940,91	51,697,949
17			PAK-M-TIH	31-12-23	US\$	13,657,282	-		
18	<a href="#">Solomon Islands</a>	TB	SLB-T-MOH	31-12-23	US\$	1,193,480	-	5,664,905	480,000
19	Tanzania (United Republic)	<a href="#">HIV/AIDS</a>	TZA-H-MOF	31-12-23	US\$	352,484,424	9,892,190	HIV: 153,341,163; TB: 29,350,390	75,915,823
20		<a href="#">HIV/TB</a>	TZA-C-Amref	31-12-23	US\$	34,268,459	8,007,810		
21		<a href="#">TB</a>	TZA-T-MOF	31-12-23	US\$	42,055,633	3,000,000		
22		<a href="#">Malaria</a>	TZA-M-MOFP	31-12-23	US\$	179,362,012	-	34,428,653	
23	Timor-Leste	<a href="#">HIV/AIDS</a>	TLS-H-MOH	31-12-23	US\$	3,465,299	-	2,839,107	2,667,312
24		<a href="#">TB</a>	TLS-T-MOH	31-12-23	US\$	8,348,220	-	2,750,531	4,498,973
25	<a href="#">Venezuela</a>	Malaria	VEN-M-UNDP	31-12-23	US\$	19,800,000	-	N/A	17,643,315
26	<a href="#">Zambia</a>	Malaria	ZMB-M-CHAZ	31-12-23	US\$	21,854,574	-	114,329,476	34,622,192
27			ZMB-M-MOH	31-12-23	US\$	43,276,586	-		

<sup>5</sup> The Grant names are subject to change based on the ISO code.

<sup>6</sup> The Program budget for the Grant may be higher than the Program budget being recommended to the Board for approval where Covid-19 Response Mechanism funding has been integrated into the Grant.

<sup>7</sup> Domestic commitments pertain to the disease programs and exclude other specific commitments for RSSH, unless otherwise specified. Commitments for disease specific programs and RSSH are subject to local currency value fluctuation against US dollar and Euro currencies. Please note that the domestic commitments included in this report are recorded as of GAC date and may be updated during implementation for countries that have been granted policy flexibilities.

